Dr. David Sinclair returns to discuss ER-100, the first partial epigenetic-reprogramming therapy to enter human clinical trials. He explains how three Yamanaka factors restored visual function in animal studies, why the first trial targets optic-nerve diseases, and what this could mean for treating other diseases associated with aging. The episode offers a look at a milestone in longevity science.
This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.
Novel
•
ER-100: First Partial Epigenetic-Reprogramming Therapy in Human Trials
ER-100, a partial epigenetic-reprogramming therapy, has entered human clinical trials—a first for this approach.